Tapestri: The Precision Genomics Platform

Over the past 12 years, the Biotherapeutics Analytical Summit has established a forum for analytical scientists to explore new tools, novel approaches and best practices to speed innovation. Living in a pandemic era, scientists are even more determined to share their research and find opportunities to collaborate and advance drug development.

After watching this webinar, participants will understand: current clinical evidence for the percutaneous treatment of structural heart disease; indications for the transcatheter treatment of symptomatic, significant aortic valve stenosis or mitral regurgitation; optimal patient selection for left atrial appendage occlusion; and the recommended training pathways for structural heart disease.

The benefits of multiplex immunohistochemistry assays for tissue analysis are numerous. High-level multiplexing, whole slide imaging, workflow compatibility, and spatial analysis are all must-have requirements for effective multiplex IHC solutions. This webinar will provide insight into how Ultivue’s InSituPlex® technology addresses each of these needs and current challenges to enable researchers to unmask the true biology of tissue samples.

Gain an understanding of how to help maintain the proper ethical pain management of patients. We are practicing in the midst of a national crisis in which every day over 130 people in the US die of overdosing from narcotic prescriptions overdose, heroin, and other related drugs. The pain was described as the "5th vital sign" by some drug companies in the 1990s and stated that patients would not be addicted to pain killers and providers began to overprescribe them in order to adequately treat pain. Approximately one-third of the chronic opioid user for none malignant pains misuse them. The incidence of neonatal abstinence syndrome has been on the rise due to widespread opioid use. CDC has published new guidelines as for how to counteract this crisis and regulatory agencies including states medical boards and DEA has increased enforcement against irresponsible and fraudulent opioid prescription writers to include license revocations and jail terms.